Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its competitor.
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its competitor.
What's Your Reaction?
